Voyager Therapeutics, Inc. Q3 FY2024 earnings call

• Voyager leverages human genetics to discover transformative medicines for neurological diseases. Pillars include a pipeline of 4 wholly-owned and 14 partnered programs. Completed enrollment/dosing in VY7523 trial for Alzheimer's. Encouraging third-party data on anti-tau antibody. • TRACER platform for AAV capsids, expecting INDs for three programs next year. • Blue chip partnerships with Neurocrine, Novartis, etc. • Exploring non-viral genetic medicines. • Tau targeting programs: Antibody approach (VY7523) with completed SAD trial enrollment; gene therapy approach (tau silencing gene therapy) shows robust reductions in human tau mRNA/protein in mice.

No specific financial performance data for product segments provided in the transcript.

• Cash position of $345M at end of Q3, expected runway into 2027. • Planned INDs for three TRACER platform programs next year. • SOD1 silencing gene therapy trial could generate proof of concept based on biomarkers, timing forthcoming. • Tau silencing gene therapy on track for US IND and Health Canada CTA filings in 2026.

• Forward-looking statements are subject to risks and uncertainties; actual results may differ materially. • Need to consult SEC filings for detailed risk factors.

Q: Congrats on the progress. Curious about tau PET imaging translation to cognitive improvements and selecting patients.

A: Toby Ferguson mentioned tau PET imaging is critical, and selecting patients with appropriate tau burden is important. Al Sandrock added relationship between tau PET effects and clinical outcomes is agnostic to drug, and selecting right patients key.

Q: Follow up on SOD1 silencing gene therapy trial timing for biomarkers.

A: Toby Ferguson said timing not guided, but results reasonably forthcoming. Al Sandrock mentioned effects on SOD1 levels in spinal fluid in about 12 weeks, and plasma neurofilament in six months.

Q: Accounting question on Novartis and Neurocrine payments.

A: Nathan Jorgensen said booked in fourth quarter.

Q: About blood-brain shuttle programs.

A: Alfred Sandrock and Todd Carter said in preclinical stages, excited about potential, not close to clinic yet. Todd Carter mentioned receptors and potential for different receptors for different diseases.

Q: Plans for 7523 match study in 2025.

A: Toby Ferguson said SAD study in healthy volunteers focuses on PK, immunogenicity, and safety to pick doses for MAD study.

Q: Thoughts on read across from bepranemab data to 7523 program.

A: Al Sandrock said bepranemab data shows antibody approach can affect tau biology, our antibody specific for pathological tau. Todd Carter added importance of PK-PD relationship data.

Q: Prioritizing 7523 vs tau silencing gene therapy and combining with anti-amyloid.

A: Toby Ferguson said both high priorities, combination possible for patients with partial/non-response to anti-amyloid.

Q: Plans for preclinical testing of C-terminal antibodies and inclusion criteria for inpatient study.

A: Alfred Sandrock said open to preclinical testing of other antibodies, and open to more stringent inclusion criteria in inpatient study. Toby Ferguson added on bepranemab data and tau burden subgroups.

Q: Appropriate patients for 7523, differences between tau KD and antibodies, track for tau silencing gene therapy, and Voyager platform advantages.

A: Alfred Sandrock on appropriate patients, Toby Ferguson and Todd Carter on preclinical progress, differentiation, and Voyager platform advantages.